Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery

Published by Expert Opinion on Drug Discovery

ADMEDose EstimationLead OptimisationPharmacokineticsPK or PDTarget Validation

The aim of this article is to provide a framework to facilitate apposite human PK and dose predictions as a continuum during drug discovery. Firstly, for early Dose Estimation to guide compound design, accelerate decision-making and focus strategy, a simple PK model is proposed based on achieving and maintaining average steady-state concentrations (Css,av) related to a measure of efficacious concentration. A toolbox of methods for the prediction of PK parameters is provided with consideration of the appropriate and effective use. Finally, advances in the understanding of compound properties and TPP will inform model selection for dose projection.

View this resource Bookmark this resource

Committee for Medicinal Products for Human Use (CHMP) Role of pharmacokinetics in the development of medicinal products in the paediatric population 2006 Doc. Ref. EMEA/CHMP/EWP/147013/2004.

Published by European Medicines Agency

  AdolescentsChildrenDose FindingExtrapolationInfantsNewbornsPharmacokineticsToddlers

This document provides advice on the use of pharmacokinetic studies in paediatric drug development and on methodological issues concerning pharmacokinetic studies in paediatric patients.

View this resource Bookmark this resource